Sarah Schmidt August 27, 2010
OTTAWA: The developer of genetically engineered salmon for human
consumption is now setting its sights on Health Canada, after U.S.
regulators on Wednesday announced their review of AquaBounty
Technologies Inc.’s historic application for the American market is
The U.S. Food and Drug Administration published details of the last
stages of its review for AquAdvantage Salmon, made from eggs produced
in a hatchery in Prince Edward Island. The genetically engineered fish
can grow at twice the normal rate, and the company, headquartered in
Massachusetts with Canadian operations in P.E.I. and Newfoundland and
Labrador, has been trying for a decade to get approval to become the
first genetically engineered animal that people would eat.
After the FDA’s special veterinary medicine committee convenes next
month to consider issues of animal health, food safety, environmental
concerns, and data validating the claim that AquAdvantage Salmon grow
faster than their conventionally bred counterparts, the Center for
Food Safety and Applied Nutrition will lead a public hearing to
consider legal issues around labelling, should the AquAdvantage Salmon
be approved in the next few months.
“We’re very encouraged,” AquaBounty president and chief executive
officer Ronald Stotish said in an interview Wednesday of the FDA review.
“This is the first food animal, we hope the world’s first FDA-approved
genetically modified food animal.”